MOONLAKE IMMUNOTHERAPEUTICS Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $118.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-10
- MOONLAKE IMMUNOTHERAPEUTICS proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $59.07M, a 71.31% decline year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $59.17M, a 59.15% decline year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $29.26M.
- MOONLAKE IMMUNOTHERAPEUTICS proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $88.40M, a 0.92% increase year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $468.40M, a 222.58% increase from fiscal 2024.
- MOONLAKE IMMUNOTHERAPEUTICS proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $145.20M, a 3.73% decline from fiscal 2023.
- MOONLAKE IMMUNOTHERAPEUTICS proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $150.83M, a 1423.34% increase from fiscal 2022.
- MOONLAKE IMMUNOTHERAPEUTICS proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $9.90M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month as first filed | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month as first filed | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month as first filed | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 10 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $59.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $118.24M 10-Q · filed 2026-08-10 | $147.49M derived: sum of 3 quarters · filed 2026-08-10 | $235.90M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2026-03-31 | $59.17M 10-Q · filed 2026-05-11 | $88.42M derived: sum of 2 quarters · filed 2026-05-11 | $176.82M derived: sum of 3 quarters · filed 2026-05-11 | $382.74M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2025-12-31 | $29.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $117.66M derived: sum of 2 quarters · filed 2026-02-25 | $323.57M derived: sum of 3 quarters · filed 2026-08-10 | $468.40M 10-K · filed 2026-02-25 | |||||
| 2025-09-30 | $88.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $294.32M derived: sum of 2 quarters · filed 2026-08-10 | $439.14M 10-Q · filed 2025-11-05 | $438.93M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2025-06-30 | $205.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $350.74M 10-Q · filed 2026-08-10 | $350.53M derived: sum of 3 quarters · filed 2026-08-10 | $438.13M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2025-03-31 | $144.83M 10-Q · filed 2026-05-11 | $144.62M derived: sum of 2 quarters · filed 2026-05-11 | $232.21M derived: sum of 3 quarters · filed 2026-05-11 | $230.91M derived: sum of 4 quarters · filed 2026-05-11 | |||||
| 2024-12-31 | -$211.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $87.38M derived: sum of 2 quarters · filed 2026-02-25 | $86.08M derived: sum of 3 quarters · filed 2026-02-25 | $145.20M 10-K · filed 2026-02-25 | $145.20M 10-K · filed 2025-02-26 | ||||
| 2024-09-30 | $87.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $86.29M derived: sum of 2 quarters · filed 2025-11-05 | $145.41M 10-Q · filed 2025-11-05 | $145.41M 10-Q · filed 2024-11-07 | $262.57M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | -$1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $57.82M 10-Q · filed 2025-08-05 | $57.82M 10-Q · filed 2024-08-07 | $174.97M derived: sum of 3 quarters · filed 2026-02-25 | $176.33M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | $59.12M 10-Q · filed 2025-05-12 | $59.12M 10-Q · filed 2024-05-07 | $176.27M derived: sum of 2 quarters · filed 2026-02-25 | $177.63M derived: sum of 3 quarters · filed 2026-02-25 | $190.31M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | $117.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $118.51M derived: sum of 2 quarters · filed 2026-02-25 | $131.18M derived: sum of 3 quarters · filed 2026-02-25 | $150.83M 10-K · filed 2026-02-25 | $150.83M 10-K · filed 2024-02-29 | ||||
| 2023-09-30 | $1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $14.03M derived: sum of 2 quarters · filed 2024-11-07 | $33.68M 10-Q · filed 2024-11-07 | $43.58M derived: sum of 4 quarters · filed 2025-02-26 | |||||
| 2023-06-30 | $12.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $32.32M 10-Q · filed 2024-08-07 | $42.23M derived: sum of 3 quarters · filed 2025-02-26 | $42.23M derived: sum of 4 quarters · filed 2025-02-26 | |||||
| 2023-03-31 | $19.65M 10-Q · filed 2024-05-07 | $29.55M derived: sum of 2 quarters · filed 2025-02-26 | $29.55M derived: sum of 3 quarters · filed 2025-02-26 | $29.55M derived: sum of 4 quarters · filed 2025-02-26 | |||||
| 2022-12-31 | $9.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $9.90M derived: sum of 2 quarters · filed 2025-02-26 | $9.90M derived: sum of 3 quarters · filed 2025-02-26 | $9.90M 10-K · filed 2025-02-26 | |||||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | ||||||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | |||||||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | ||||||||
| 2021-12-31 | $0.00 10-K · filed 2023-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |